Breyanzi won approval in these new indications based on results from the pivotal TRANSCENT CLL 004 trial, where treatment with the CAR-T therapy elicited a complete response rate of 20% and an overall response rate of 45%, with responses lasting more than 35 months
Furthermore, the microgels demonstrated good temperature-responsive properties
The CRISPR-Cas9 screen demonstrated a significant reliance of ATLL cells on mTORC1 signaling
PlexusDx offers personalized semaglutide therapy at $189/mo month-to-month, or from $149/mo on the 6-month plan, with flexible dosing support and provider guidance to help you maintain consistency without stress
Prone positioning during extracorporeal membrane oxygenation in patients with severe ARDS: The PRONECMO randomized clinical trial
This biological limitation is one of the primary reasons experts remain cautious when patients ask whether GLP-1 patches work compared to injectable GLP-1 therapy